Medical Services | Addiction Professional Magazine Skip to content Skip to navigation

Medical Services

Printer-friendly version

Editors Picks

Opioid adulterants now affecting cocaine supply

December 18, 2017  |  Gary A. Enos, Editor
news
Reports from federal officials in Florida raise concerns about the potential deadliness of the cocaine supply.

Caron's new medical center speaks to complex care needs

December 6, 2017  |  Gary A. Enos, Editor
article
Caron Treatment Centers has established a medical hub on its main campus as it continues to see cases of growing complexity.

Cocaine prominent in Florida report on drug deaths

December 4, 2017  |  Gary A. Enos, Editor
news
According to a state of Florida report, deaths involving and caused by cocaine showed significant increases from 2015 to 2016.

FDA approves once-monthly injectable buprenorphine product

December 1, 2017  |  Tom Valentino, Senior Editor
article
The FDA has approved a once-monthly injectable form of buprenorphine for the treatment of opioid use disorder, but clinicians are lukewarm on its use.

FDA seeks to encourage development of abuse-deterrent opioid formulations

November 24, 2017  |  Gary A. Enos, Editor
news
The Food and Drug Administration (FDA) this week announced several steps designed to remove barriers to access to abuse-deterrent formulations of opioids.

States eye adding gabapentin to controlled substance list

November 22, 2017  |  Rachael Zimlich, RN, Contributing Writer
article
Reports of increasing misuse of gabapentin, usually in combination with opioids or other drugs, have caught the attention of a number of state regulators.

Head of FDA has harsh words about kratom use

November 17, 2017  |  Gary A. Enos, Editor
article
A public health advisory issued this week by the Food and Drug Administration (FDA) has re-intensified controversy over use of the plant-based product kratom.

Drug studies' results make case for access to all opioid dependence medications

November 16, 2017  |  Gary A. Enos, Editor
article
Recent efficacy and safety studies found comparable and encouraging results for buprenorphine and injectable naltrexone in the treatment of opioid dependence.

FDA clears electrical device to combat opioid withdrawal

November 15, 2017  |  Gary A. Enos, Editor
news
The Food and Drug Administration (FDA) today announced that an electrical stimulation device attached to the ear can be marketed for the treatment of symptoms of opioid withdrawal.

Hospital boosts opioid patients' rapid access to medication

November 14, 2017  |  Gary A. Enos, Editor
article
The experience of Boston Medical Center bolsters evidence that hospitalized patients with opioid use disorders can be successfully initiated on medication before discharge.

Record-setting amount of prescriptions collected on Take Back Day

November 7, 2017  |  Tom Valentino, Senior Editor
news
More than 456 tons of unwanted medications were collected for safe disposal during the U.S. Drug Enforcement Administration’s 14th Prescription Drug Take Back Day.

Injectable buprenorphine moves closer to approval

November 2, 2017  |  Gary A. Enos, Editor
news
It appears likely that the first monthly injectable formulation of buprenorphine to treat opioid dependence will receive federal approval by the end of this month.